Patents by Inventor Eric Franklin ZHU

Eric Franklin ZHU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
    Publication number: 20210283217
    Abstract: Described herein are methods for treating a subject having or at risk of developing an autoimmune or inflammatory condition or an infection by administering a neuromodulating agent.
    Type: Application
    Filed: July 25, 2017
    Publication date: September 16, 2021
    Inventors: Erica WEINSTEIN, Jordi MATA-FINK, Avak KAHVEJIAN, Noubar B. AFEYAN, Laura Kristina JEANBART, Alexandra LANTERMANN, Jonathan Barry HUROV, Manuel Andreas FANKHAUSER, Chengyi J. SHU, Eric Franklin ZHU
  • NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE
    Publication number: 20210154272
    Abstract: Described herein are methods for treating a subject having or at risk of developing cancer administering a neuromodulating agent.
    Type: Application
    Filed: October 5, 2020
    Publication date: May 27, 2021
    Inventors: Erica WEINSTEIN, Jordi MATA-FINK, Avak KAHVEJIAN, Noubar B. AFEYAN, Laura Kristina JEANBART, Alexandra LANTERMANN, Jonathan Barry HUROV, Manuel Andreas FANKHAUSER, Chengyi J. SHU, Eric Franklin ZHU
  • Methods and compositions for treating cancer using SERCA pump inhibitors
    Patent number: 11013717
    Abstract: The present invention provides methods for treating cancer using sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump inhibitors, such as SERCA pump inhibitory antibodies, among others. The invention also features compositions containing SERCA pump inhibitors, methods of diagnosing patients with SERCA pump-associated cancer, and methods of predicting the response of cancer in a subject to treatment with SERCA pump inhibitors.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: May 25, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, Eric Franklin Zhu, Katherine Mary Molloy
  • NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE
    Publication number: 20190240293
    Abstract: Described herein are methods for treating a subject having or at risk of developing cancer administering a neuromodulating agent.
    Type: Application
    Filed: July 25, 2017
    Publication date: August 8, 2019
    Inventors: Erica WEINSTEIN, Jordi MATA-FINK, Avak KAHVEJIAN, Noubar B. AFEYAN, Laura Kristina JEANBART, Alexandra LANTERMANN, Jonathan Barry HUROV, Manuel Andreas FANKHAUSER, Chengyi J. SHU, Eric Franklin ZHU
  • PROTEIN-CHAPERONED T-CELL VACCINES
    Publication number: 20170252417
    Abstract: Protein antigens are provided. The protein antigens typically include a peptide antigen conjugated or fused to a chaperone protein to form a “chaperone-antigen” that increases lymph node uptake; improves an immune response; or a combination thereof relative to the peptide antigen alone. The immune response can be, for example, increased antigen-specific proliferation, enhanced cytokine production, stimulation of differentiation and/or effector functions, promotion of survival, rescue from exhaustion and/or anergy of T cells, or a combination thereof. Chaperon-antigens can also be used to induce tolerance and increase immune suppressive responses. In the most preferred embodiments, the peptide antigen is fused to the chaperone protein to form a fusion protein. The “chaperone-antigen” can be combined with an adjuvant to form a vaccine and administered to a subject to modulate an immune response to the antigen.
    Type: Application
    Filed: March 7, 2017
    Publication date: September 7, 2017
    Inventors: Darrell Irvine, Karl Dane Wittrup, Naveen K. Mehta, Kavya Rakhra, Eric Franklin Zhu
  • SYNERGISTIC TUMOR TREATMENT WITH EXTENDED-PK IL-2 AND ADOPTIVE CELL THERAPY
    Publication number: 20150017120
    Abstract: The present invention provides a method of enhancing adoptive cell therapy (ACT) by administering an extended-pharmacokinetic (PK) interleukin (IL)-2 to a cancer subject receiving ACT, optionally in combination with a therapeutic antibody. Methods of treating cancer and promoting tumor regression are also provided.
    Type: Application
    Filed: June 13, 2014
    Publication date: January 15, 2015
    Inventors: Karl Dane WITTRUP, Cary Francis OPEL, Eric Franklin ZHU, Shuning GAI